The Food & Drug Administration is easing some of its guidelines on what can be labeled as having "no artificial colors." In a ...
The U.S. Food and Drug Administration has approved Yuvezzi (carbachol and brimonidine tartrate) ophthalmic solution 2.75%/0.1 ...
Pharmaceutical Technology on MSN
Rare paediatric disease voucher programme makes long-awaited US return
After more than a year out in the cold, the programme’s reauthorisation is a boost for rare disease therapy developers.
Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity February ...
Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of ...
On February 1, 2026, the Food and Drug Administration (FDA) officially started accepting requests to participate in the FDA PreCheck pilot ...
If the FDA follows through with the proposed guidelines, and they are not fatally twisted by pressure from the medical ...
The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic pulmonary fibrosis into its Biomarker Qualification Program, according to a press ...
Mayo Clinic’s Chelsee Jensen, PharmD, discusses FDA policy changes, biosimilar development hurdles, denosumab lessons, and ...
The West Virginia House of Delegates and Mississippi House of Representatives have both approved bills to support research in ...
The FDA laid out the qualifications a site would need to qualify for PreCheck on a webpage where companies can also submit requests to take part in the program. Companies are limited to one submission ...
February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results